Literature DB >> 25134672

Belinostat: first global approval.

Raewyn M Poole1.   

Abstract

Belinostat [Beleodaq(®) (US)], a small-molecule hydroxamate-type inhibitor of class I, II and IV histone deacetylase (HDAC) enzymes, has been developed by TopoTarget and Spectrum Pharmaceuticals for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). Belinostat has received its first global approval as monotherapy for this indication in the US, under the Food and Drug Administration's accelerated approval program. This article summarizes the milestones in the development of belinostat leading to this first approval for the treatment of PTCL.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25134672     DOI： 10.1007/s40265-014-0275-8

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  52 in total

Review 1.  Histone deacetylase inhibitors in the treatment of lymphoma.

Authors:  Manuela Lemoine; Anas Younes
Journal:  Discov Med       Date:  2010-11       Impact factor: 2.970

2.  Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors.

Authors:  Giuseppe Giaccone; Arun Rajan; Arlene Berman; Ronan J Kelly; Eva Szabo; Ariel Lopez-Chavez; Jane Trepel; Min-Jung Lee; Liang Cao; Igor Espinoza-Delgado; John Spittler; Patrick J Loehrer
Journal:  J Clin Oncol       Date:  2011-04-18       Impact factor: 44.544

3.  The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo.

Authors:  Anthony Tumber; Laura S Collins; Kamille Dumong Petersen; Annemette Thougaard; Sanne J Christiansen; Marielle Dejligbjerg; Peter Buhl Jensen; Maxwell Sehested; James W A Ritchie
Journal:  Cancer Chemother Pharmacol       Date:  2006-11-24       Impact factor: 3.333

4.  Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.

Authors:  Jianming Duan; Jay Friedman; Liesl Nottingham; Zhong Chen; Gulshan Ara; Carter Van Waes
Journal:  Mol Cancer Ther       Date:  2007-01       Impact factor: 6.261

5.  Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.

Authors:  Vivien Mak; Jeremey Hamm; Mukesh Chhanabhai; Tamara Shenkier; Richard Klasa; Laurie H Sehn; Diego Villa; Randy D Gascoyne; Joseph M Connors; Kerry J Savage
Journal:  J Clin Oncol       Date:  2013-04-22       Impact factor: 44.544

6.  Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group.

Authors:  Winnie Yeo; Hyun C Chung; Stephen L Chan; Ling Z Wang; Robert Lim; Joel Picus; Michael Boyer; Frankie K F Mo; Jane Koh; Sun Y Rha; Edwin P Hui; Hei C Jeung; Jae K Roh; Simon C H Yu; Ka F To; Qian Tao; Brigette B Ma; Anthony W H Chan; Joanna H M Tong; Charles Erlichman; Anthony T C Chan; Boon C Goh
Journal:  J Clin Oncol       Date:  2012-08-20       Impact factor: 44.544

Review 7.  Epigenetics and cancer.

Authors:  Anders H Lund; Maarten van Lohuizen
Journal:  Genes Dev       Date:  2004-10-01       Impact factor: 11.361

8.  Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment.

Authors:  Shu-Fu Lin; Jen-Der Lin; Ting-Chao Chou; Yu-Yao Huang; Richard J Wong
Journal:  PLoS One       Date:  2013-10-14       Impact factor: 3.240

9.  Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral T-cell lymphoma.

Authors:  Peter Reimer; Shanta Chawla
Journal:  J Hematol Oncol       Date:  2013-09-10       Impact factor: 17.388

10.  Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer.

Authors:  Makoto Sudo; Tan Min Chin; Seiichi Mori; Ngan B Doan; Jonathan W Said; Makoto Akashi; H Phillip Koeffler
Journal:  Cancer Chemother Pharmacol       Date:  2013-03-21       Impact factor: 3.333
View more
  37 in total

1.  Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling.

Authors:  Samuel Bouchet; Camille Linot; Dusan Ruzic; Danica Agbaba; Benoit Fouchaq; Joëlle Roche; Katarina Nikolic; Christophe Blanquart; Philippe Bertrand
Journal:  ACS Med Chem Lett       Date:  2019-05-09       Impact factor: 4.345

Review 2.  Metal-dependent Deacetylases: Cancer and Epigenetic Regulators.

Authors:  Jeffrey E López; Eric D Sullivan; Carol A Fierke
Journal:  ACS Chem Biol       Date:  2016-03-18       Impact factor: 5.100

3.  HDAC8 substrate selectivity is determined by long- and short-range interactions leading to enhanced reactivity for full-length histone substrates compared with peptides.

Authors:  Carol Ann Castañeda; Noah A Wolfson; Katherine R Leng; Yin-Ming Kuo; Andrew J Andrews; Carol A Fierke
Journal:  J Biol Chem       Date:  2017-11-06       Impact factor: 5.157

4.  Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer.

Authors:  Ferdinando Chiaradonna; Iros Barozzi; Claudia Miccolo; Gabriele Bucci; Roberta Palorini; Lorenzo Fornasari; Oronza A Botrugno; Giancarlo Pruneri; Michele Masullo; Alfonso Passafaro; Viviana E Galimberti; Valeria R Fantin; Victoria M Richon; Salvatore Pece; Giuseppe Viale; Pier Paolo Di Fiore; Giulio Draetta; Pier Giuseppe Pelicci; Saverio Minucci; Susanna Chiocca
Journal:  Antioxid Redox Signal       Date:  2015-05-27       Impact factor: 8.401

5.  Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors.

Authors:  Tao Liang; Xuben Hou; Yi Zhou; Xinying Yang; Hao Fang
Journal:  ACS Med Chem Lett       Date:  2019-07-05       Impact factor: 4.345

6.  WMJ-8-B, a novel hydroxamate derivative, induces MDA-MB-231 breast cancer cell death via the SHP-1-STAT3-survivin cascade.

Authors:  Yu-Fan Chuang; Shiu-Wen Huang; Ya-Fen Hsu; Meng-Chieh Yu; George Ou; Wei-Jan Huang; Ming-Jen Hsu
Journal:  Br J Pharmacol       Date:  2017-08-01       Impact factor: 8.739

Review 7.  Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review.

Authors:  Ahmed Sawas; Dejan Radeski; Owen A O'Connor
Journal:  Ther Adv Hematol       Date:  2015-08

8.  Epigenetic Regulation of Multidrug Resistance Protein 1 and Breast Cancer Resistance Protein Transporters by Histone Deacetylase Inhibition.

Authors:  Dahea You; Jason R Richardson; Lauren M Aleksunes
Journal:  Drug Metab Dispos       Date:  2020-03-19       Impact factor: 3.922

9.  Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo.

Authors:  Wenxiu Qi; Wenbo Zhang; Holly Edwards; Roland Chu; Gerard J Madlambayan; Jeffrey W Taub; Zhihong Wang; Yue Wang; Chunhuai Li; Hai Lin; Yubin Ge
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

10.  Molecular, biological characterization and drug sensitivity of chidamide-resistant non-small cell lung cancer cells.

Authors:  Song'e Luo; Kai Ma; Hongxia Zhu; Shuren Wang; Mei Liu; Weina Zhang; Shufang Liang; Ningzhi Xu
Journal:  Oncol Lett       Date:  2017-09-26       Impact factor: 2.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.